Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

被引：301

作者：

Million, Matthieu ^{[1
,2
]}

Lagier, Jean-Christophe ^{[1
,2
]}

Gautret, Philippe ^{[1
,3
]}

Colson, Philippe ^{[1
,2
]}

Fournier, Pierre-Edouard ^{[1
,3
]}

Amrane, Sophie ^{[1
,2
]}

Hocquart, Marie ^{[1
]}

Mailhe, Morgane ^{[1
]}

Esteves-Vieira, Vera ^{[1
]}

Doudier, Barbara ^{[1
]}

Aubry, Camille ^{[1
]}

Correard, Florian ^{[4
,5
]}

Giraud-Gatineau, Audrey ^{[1
,3
,6
,7
]}

Roussel, Yanis ^{[1
,2
]}

Berenger, Cyril ^{[1
,3
]}

Cassir, Nadim ^{[1
,2
]}

Seng, Piseth ^{[1
,2
]}

Zandotti, Christine ^{[1
]}

Dhiver, Catherine ^{[1
]}

Ravaux, Isabelle ^{[1
]}

Tomei, Christelle ^{[1
]}

Eldin, Carole ^{[1
,3
]}

Tissot-Dupont, Herve ^{[1
]}

Honore, Stephane ^{[4
,5
]}

Stein, Andreas ^{[1
,2
]}

Jacquier, Alexis ^{[8
]}

Deharo, Jean-Claude ^{[9
]}

Chabriere, Eric ^{[1
,2
]}

Levasseur, Anthony ^{[1
,2
]}

Fenollar, Florence ^{[1
,3
]}

Rolain, Jean-Marc ^{[1
,2
]}

Obadia, Yolande ^{[1
]}

Brouqui, Philippe ^{[1
,2
]}

Drancourt, Michel ^{[1
,2
]}

La Scola, Bernard ^{[1
,2
]}

Parola, Philippe ^{[1
,3
]}

Raoult, Didier ^{[1
,2
]}

机构：

[1] IHU Mediterranee Infect, 19-21 Blvd Jean Moulin, F-13005 Marseille, France

[2] Aix Marseille Univ, MEPHI, AP HM, IRD, Marseille, France

[3] Aix Marseille Univ, VITROME, SSA, AP HM,IRD, Marseille, France

[4] Aix Marseille Univ, Lab Pharm Clin, Marseille, France

[5] Hop La Timone, AP HM, Serv Pharm, Marseille, France

[6] Ctr Epidemiol & Sante Publ Armees CESPA, Marseille, France

[7] AP HM, Marseille, France

[8] Aix Marseille Univ, CRMBM CEMEREM Ctr Resonance Magnet Biol & Med, Dept Radiol & Cardiovasc Imaging, CNRS,Ctr Explorat Metab Resonance Magnet,UMR 7339, Marseille, France

[9] Aix Marseille Univ, Hop Timone, AP HM, Cardiol,Rythmol, Marseille, France

来源：

TRAVEL MEDICINE AND INFECTIOUS DISEASE | 2020年 / 35卷

关键词：

SARS-CoV-2; COVID-19; Hydroxychloroquine; Azithromycin;

D O I：

10.1016/j.tmaid.2020.101738

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background: In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19. Methods: We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days). Outcomes were death, clinical worsening (transfer to ICU, and 10 day hospitalization) and viral shedding persistence (> 10 days). Results: A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years - range 14 -95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74 -95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta - blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision). Conclusion: Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients.

引用

页数：9

共 28 条

[21]

Sung-sun K., 2020, KOREA BIOMEDICAL REV

[22]

Tang W., 2020, High Performance Computing for Geospatial Applications, P1

[23] Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model [J].

Toth, Karoly ;

Spencer, Jacqueline F. ;

Dhar, Debanjan ;

Sagartz, John E. ;

Buller, R. Mark L. ;

Painter, George R. ;

Wold, William S. M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (20) :7293-7297

[24]

Touret F., 2020, IN VITRO SCREENING F, DOI [10.1101/2020.04.03.023846, DOI 10.1101/2020.04.03.023846]

[25]

Weston S, 2020, BIORXIV, DOI [DOI 10.1101/2020.03.25.008482, 10.1101/2020.03.25.008482]

[26] Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [J].

Wu, Zunyou ;

McGoogan, Jennifer M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (13) :1239-1242

[27]

Yao X, 2020, CLIN INFECT DIS, V2

[28] Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [J].

Zhou, Fei ;

Yu, Ting ;

Du, Ronghui ;

Fan, Guohui ;

Liu, Ying ;

Liu, Zhibo ;

Xiang, Jie ;

Wang, Yeming ;

Song, Bin ;

Gu, Xiaoying ;

Guan, Lulu ;

Wei, Yuan ;

Li, Hui ;

Wu, Xudong ;

Xu, Jiuyang ;

Tu, Shengjin ;

Zhang, Yi ;

Chen, Hua ;

Cao, Bin .

LANCET, 2020, 395 (10229) :1054-1062

← 1 2 3 →